12.06.23 -- What's Next For RNA Therapeutics?

Join industry experts December 14 as they discuss the strategic, conceptual, and operational implications of the shift toward risk-based monitoring in the ICH E6(R3) draft guidelines and what sponsors and vendor partners should already be doing to thrive in the future of clinical trial management. Click here to learn more.

Leveraging Little’s Law to quantify metrics that otherwise would be causing confusion and process interruption can help to reduce wait times and deliver materials on time and within budget.

Learn to modernize and streamline the technology solutions that empower client service, research study and project management, and overall operational efficiency.

While this critical decision is not novel for the life sciences, the factors impacting it change year to year and have become increasingly complex.

Drugs have become more lipophilic and complex in structure over time. Innovative strategies are needed to improve bioavailability of these new drugs.